Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 Giugno;53(3) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 Giugno;53(3):348-55

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Periodicità: Trimestrale

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 Giugno;53(3):348-55

TREATMENT OF HCC AND LIVER METASTASES BY MEANS OF RADIONUCLIDE THERAPY 

 REVIEW

131-iodine Lipiodol therapy in hepatocellular carcinoma

Raoul J.-L. 1,2, Boucher E. 1, Roland Y. 3, Garin E. 2,3

1 Department of Medical Oncology Comprehensive Cancer Centre E Marquis, Rennes, France
2 European University in Brittany, Rennes, France
3 Department of Radiology and Nuclear Medicine Comprehensive Cancer Centre E Marquis, Rennes, France

Hepatocellular carcinoma (HCC) is a major health concern worldwide. Several therapeutic options are available, but transplantation is the only curative option; for the vast majority of patients, the remaining alternative is palliative care. There is some hope however with Lipiodol which, when injected into the hepatic artery remains concentrated in the liver and specifically within the malignant tumor for a long period of time. This feature has been used for internal radiation therapy using 131Iodine-labeled Lipiodol. Phase III studies with 131I-Lipiodol have demonstrated, in an adjuvant setting improved recurrence-free and overall survival compared with surgery alone and in a palliative setting improved survival among patients with portal thrombosis. Comparison with chemoembolization has shown similar results in terms of efficacy but with better tolerance for 131I-lipiodol. The method would also be useful for small nodules not amendable to surgery or percutaneous treatment. The use of another radionuclide, 188Re, could probably improve the current method by reducing the need for radioprotection. New perspectives will be forthcoming with the advent of targeted drugs using combinations in sequential or concomitant regimens.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina